Key result
Transcatheter closure of PFOs and ASDs shows safety and efficacy with ~2% recurrent embolic events.
Why the study?
Immediate and midterm results of transcatheter closure of ASDs and PFOs using various closure devices needed evaluation.
Comparison
Closure using Amplatzer vs Occlutech Figulla vs BioSTAR devices
Design
Cohort study
Follow-up
Median 43 months for ASD and 30 months for PFO
Authors
Loading...
Supports real-world safety of PFO and ASD closure; extends observational evidence but leaves randomized outcome data open.
Cohort (n=414)
Transcatheter closure of PFOs and secundum ASDs using contemporary devices is safe and effective, demonstrating low rates of midterm complications.
Aytemir et al. (2013) conducted a cohort in Atrial septal defects (ASDs) and patent foramen ovale (PFO) (n=414). Transcatheter closure using Amplatzer, Occlutech Figulla, or BioSTAR devices was evaluated on Immediate and midterm results including procedural complications, recurrent embolic events, and residual shunts. Transcatheter closure of PFOs and secundum ASDs was safe and efficacious, with procedural device embolization occurring in 0.48% and recurrent embolic events in 1.8% of PFO patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: